Accelerating Parkinson’s Disease Research and Drug Development
Learn more about the AMP PD program, a public-private partnership between government, industry, and nonprofit organizations focusing on identifying and validating biomarkers for predicting Parkinson’s disease, tracking disease progression, and validating therapeutic targets.
What is the Accelerating Medicines Partnership® Program?
The Accelerating Medicines Partnership® (AMP®) program is a bold venture between the National Institutes of Health (NIH), biopharmaceutical and life sciences companies, and nonprofit organizations aimed at transforming the current model for developing new diagnostics and treatments for disease.
The goal of the AMP program is to understand such diseases more fully through research to identify and validate novel, clinically relevant therapeutic targets. As a result, it is expected to accelerate the process of bringing new medicines to patients.
The Accellerating Medicines Partnership® program is an umbrella partnership with programs in four disease areas:
- Alzheimer’s disease
- Type 2 diabetes
- Autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus)
- Parkinson’s disease
This multi-sector partnership is managed by the Foundation for the NIH (FNIH). NIH and industry partners are sharing expertise and resources in an integrated governance structure that enables the best-informed scientific contributions from all participants. A critical component of the partnership is making AMP data publicly accessible for use by the broad research community.
What is AMP PD?
Parkinson’s disease (PD) represents a significant and increasing threat to public health. Estimates suggest that between 500,000 and 1 million Americans have Parkinson’s disease. (Neurology. 2007 Jan 30;68(5):326-37; Neurology. 2007 Jan 30;68(5):384-6; Mov Disord. 2013 Mar;28(3):311-8; NPJ Parkinsons Dis. 2018 Jul 10;4:21.). That number is expected to increase in the coming years, and the current annual cost of treatment for PD in the United States has been estimated at $14.4 billion. Although PD is a complex neurodegenerative disorder, the two primary hallmarks of the disease are the progressive loss of dopamine-containing neurons in a specific area of the brain called the substantia nigra and the buildup within neurons of a protein, α-synuclein, into clusters called Lewy bodies.
The cause of PD has been linked to several genetic, epigenetic, and environmental factors; however, the exact causes of neuronal death and Lewy body formation are not known. Despite large investments in research and development, no disease-modifying drugs have been approved for PD. It has become clear that a breakthrough in this area will require strong and transformative public-private partnerships that can produce bold discoveries.
The success of clinical trials aimed at developing new treatments for PD hinges on identifying and validating biomarkers that can track the progression of the disease. A wealth of information has been collected from individuals with PD through such programs as the NINDS’s Parkinson’s Disease Biomarkers Program (PDBP), The Michael J. Fox Foundation (MJFF)’s Parkinson’s Progression Markers Initiative, the MJFF/NINDS BioFIND cohort, and the Harvard Biomarkers Study. However, the resources, time, and cost required to perform a large-scale analysis of that data have been prohibitive for individual researchers, companies, and organizations. AMP PD will provide the expertise and support needed to determine which biomarkers show the greatest potential for predicting PD and the progression of the disease.
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.
AMP PD Budget: 5 years
|Total Project||Total NIH||Total Industry||Total Nonprofit|
22 (+2 in-kind)
8 (+2 in-kind)
AMP PD Projects
Using the AMP PD Knowledge Portal, researchers will collaborate to identify the most promising biomarkers for use in clinical trials for new treatments to affect the progression of PD. The partners will ask the following key questions in their analyses:
- Does the biomarker offer insight into the mechanism of the disease?
- Does the biomarker change over the course of PD and can it be used to track disease progression?
- Can the biomarker be used to separate PD patients into discrete groups?
- Can the biomarker be used as a prognostic indicator during early-stage PD
- Food and Drug Administration (FDA)
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institute on Aging (NIA)
The steering committee (SC) for AMP PD consists of representatives from each of the research partner organizations. The SC operates under the direction of the overall AMP Executive Committee and is organized by the FNIH.